跳至主要内容
临床试验/NCT00052416
NCT00052416已完成1 期

Thalidomide in Indolent Non-Hodgkin's Lymphoma: A Feasibility Study

Beth Israel Deaconess Medical Center4 个研究点 分布在 1 个国家开始时间: 2002年10月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
试验地点
4

研究概览

简要总结

RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.

PURPOSE: Phase I trial to determine the effectiveness of thalidomide in treating patients who have asymptomatic, indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

详细描述

OBJECTIVES:

  • Determine the feasibility, in terms of toxicity and patient compliance, of thalidomide in patients with asymptomatic, indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
  • Determine the event-free and progression-free survival of patients treated with this drug.
  • Determine disease response and time to next treatment in patients treated with this drug.
  • Determine the quality of life of patients treated with this drug.

OUTLINE: Patients receive oral thalidomide once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, monthly during study, and at the end of the study.

PROJECTED ACCRUAL: A total of 30-36 patients will be accrued for this study within 2 years.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Other

研究点 (4)

Loading locations...

相似试验